Reply to thread

Message

<blockquote data-quote="Fred&amp;#039;s Myth" data-source="post: 5678565" data-attributes="member: 55587"><p>&quot;In May 2020, the Trump Administration announced the creation of a program called Operation Warp Speed, which seeks to use coordinated government support to accelerate the development, manufacturing, and distribution of COVID-19 vaccines and other medical countermeasures.5 With respect to vaccines, the program initially selected fourteen promising candidates, which are being narrowed down to “about seven.” 6 Under Operation Warp Speed, the federal government is investing in scaling up manufacturing and distribution for selected COVID-19 vaccine candidates “at risk” (that is, before safety and efficacy is demonstrated). 7 Under the program, BARDA has entered into agreements to accelerate the development and manufacturing—and to purchase hundreds of millions of doses—for vaccine candidates being developed by AstraZeneca and the University of Oxford, 8 Sanofi and GlaxoSmithKline (GSK), 9 Pfizer and BioNTech,10 Moderna and NIAID,11 Novavax,12 and Johnson &amp; Johnson. 13 By November 2020, three of the manufacturers participating in Operation Warp Speed—Pfizer/BioNTech, Moderna/NIAID, and AstraZeneca/University of Oxford—announced encouraging safety and efficacy results from the Phase 3 trials of their vaccines.&quot;&nbsp; <a href="https://crsreports.congress.gov/product/pdf/R/R46399" target="_blank">https://crsreports.congress.gov/product/pdf/R/R46399</a></p></blockquote><p></p>

[QUOTE="Fred's Myth, post: 5678565, member: 55587"] "In May 2020, the Trump Administration announced the creation of a program called Operation Warp Speed, which seeks to use coordinated government support to accelerate the development, manufacturing, and distribution of COVID-19 vaccines and other medical countermeasures.5 With respect to vaccines, the program initially selected fourteen promising candidates, which are being narrowed down to “about seven.” 6 Under Operation Warp Speed, the federal government is investing in scaling up manufacturing and distribution for selected COVID-19 vaccine candidates “at risk” (that is, before safety and efficacy is demonstrated). 7 Under the program, BARDA has entered into agreements to accelerate the development and manufacturing—and to purchase hundreds of millions of doses—for vaccine candidates being developed by AstraZeneca and the University of Oxford, 8 Sanofi and GlaxoSmithKline (GSK), 9 Pfizer and BioNTech,10 Moderna and NIAID,11 Novavax,12 and Johnson & Johnson. 13 By November 2020, three of the manufacturers participating in Operation Warp Speed—Pfizer/BioNTech, Moderna/NIAID, and AstraZeneca/University of Oxford—announced encouraging safety and efficacy results from the Phase 3 trials of their vaccines." [URL]https://crsreports.congress.gov/product/pdf/R/R46399[/URL] [/QUOTE]

Verification